hackint0sh/temp-data huggingface dataset:
protocolSection identificationModule nctId: NCT06325839, orgStudyIdInfo id: GRU-SBF-ES-01, briefTitle: Effects of HypnoBirthing Training and Oxytocin Massage in Primiparous Pregnants, statusModule overallStatus: COMPLETED, startDateStruct date: 2023-04-01, primaryCompletionDateStruct date: 2023-09-10, completionDateStruct date: 2023-09-10, studyFirstPostDateStruct date: 2024-03-22, lastUpdatePostDateStruct date: 2024-03-22, sponsorCollaboratorsModule leadSponsor name: Giresun University, class: OTHER, descriptionModule briefSummary: This study was conducted to determine the effects of hypnobirthing training and oxytocin massage on birth and postpartum period in primiparous pregnant women., conditionsModule conditions: Pregnancy Related, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, interventionModelDescription: The research is an experimental study with a randomized control group., primaryPurpose: SUPPORTIVE_CARE, maskingInfo masking: SINGLE, maskingDescription: Pregnant women included in the study were randomly divided into two groups using the sealed envelope method., whoMasked: PARTICIPANT, enrollmentInfo count: 50, type: ACTUAL, armsInterventionsModule interventions name: HypnoBirthing training and oxytocin massage group, outcomesModule primaryOutcomes measure: Wijma Birth Anticipation/Experience Scale A (W-DEQ-A), secondaryOutcomes measure: Wijma Birth Expectancy/Expectation Scale B (W-DEQ-B), secondaryOutcomes measure: Postpartum Breastfeeding Self-Efficacy Scale - Short Form, secondaryOutcomes measure: Mother-Infant Attachment Scale (MICS), secondaryOutcomes measure: Birth satisfaction scale short form (BSS-SF), eligibilityModule sex: FEMALE, minimumAge: 18 Years, maximumAge: 45 Years, stdAges: ADULT, contactsLocationsModule locations facility: Giresun Gynecology and Children's Diseases Hospital, city: Giresun, state: Center, zip: 28200, country: Turkey, geoPoint lat: 40.91698, lon: 38.38741, hasResults: False
protocolSection identificationModule nctId: NCT06325826, orgStudyIdInfo id: GES, briefTitle: The Study of the Validation of General Evaluation Score (GES) in the Prediction of Hepatocellular Carcinoma Risk Among Patients With Advanced Fibrosis and Cirrhosis Who Achieved Sustained Virological Response for Hepatitis C Virus After Direct Acting Antiviral Drugs, statusModule overallStatus: ACTIVE_NOT_RECRUITING, startDateStruct date: 2022-02-01, primaryCompletionDateStruct date: 2023-06-30, completionDateStruct date: 2025-06-30, studyFirstPostDateStruct date: 2024-03-22, lastUpdatePostDateStruct date: 2024-03-26, sponsorCollaboratorsModule leadSponsor name: Egyptian Liver Hospital, class: OTHER, descriptionModule briefSummary: This cohort study aims to evaluate the validation of general evaluation score in the prediction of hepatocellular carcinoma risk among patients with advanced fibrosis (F3) and cirrhosis (F4) who achieved sustained virological response for hepatitis c virus after direct acting antiviral drugs and determine the group of these patients who require intensified surveillance., conditionsModule conditions: Hepatocellular Carcinoma, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 500, type: ACTUAL, armsInterventionsModule interventions name: General Evaluation Score (GES), outcomesModule primaryOutcomes measure: Hepatocellular Carcinoma, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Egyptian Liver Hospital, city: Talkha, state: Dakahlia, zip: 36681, country: Egypt, geoPoint lat: 31.0539, lon: 31.37787, hasResults: False
protocolSection identificationModule nctId: NCT06325813, orgStudyIdInfo id: CIN001 - ADHD PreSMART, briefTitle: ADHD PreSMA Response Inhibition Therapy, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-05-01, primaryCompletionDateStruct date: 2026-06-30, completionDateStruct date: 2026-12-31, studyFirstPostDateStruct date: 2024-03-22, lastUpdatePostDateStruct date: 2024-03-22, sponsorCollaboratorsModule leadSponsor name: Children's Hospital Medical Center, Cincinnati, class: OTHER, descriptionModule briefSummary: ADHD children have abnormal inhibitory control, meaning they have trouble stopping themselves from doing something they should not do. This ability to control involves an area in the brain called the pre-supplementary motor area (pre-SMA). Scientists have previously shown that the pre-SMA is abnormal in ADHD patients. In this study, we will use Transcranial Magnetic Stimulation (TMS) to stimulate the pre-SMA and determine the effects on measures that are related to inhibitory control., conditionsModule conditions: Attention Deficit Hyperactivity Disorder, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: BASIC_SCIENCE, maskingInfo masking: DOUBLE, whoMasked: PARTICIPANT, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 40, type: ESTIMATED, armsInterventionsModule interventions name: Active repetitive TMS, interventions name: Sham repetitive TMS, outcomesModule primaryOutcomes measure: TMS-based Short-Interval Intracortical Inhibition (SICI), primaryOutcomes measure: EEG-based beta activity, primaryOutcomes measure: TMS-based Cortical Silent Period (cSP), primaryOutcomes measure: EEG-based alpha activity, secondaryOutcomes measure: Stop Signal Reaction Time, eligibilityModule sex: ALL, minimumAge: 12 Years, maximumAge: 17 Years, stdAges: CHILD, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06325787, orgStudyIdInfo id: S2021-211-02, briefTitle: Image-guided Thermal Ablation vs. Lobectomy for Solitary Papillary Thyroid Microcarcinoma, statusModule overallStatus: COMPLETED, startDateStruct date: 2013-05-01, primaryCompletionDateStruct date: 2017-01-31, completionDateStruct date: 2024-01-31, studyFirstPostDateStruct date: 2024-03-22, lastUpdatePostDateStruct date: 2024-03-25, sponsorCollaboratorsModule leadSponsor name: Chinese PLA General Hospital, class: OTHER, descriptionModule briefSummary: To evaluate the clinical outcomes of image-guided thermal ablation versus thyroid lobectomy for the treatment of papillary thyroid microcarcinoma, conditionsModule conditions: Papillary Thyroid Cancer, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NON_RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 1021, type: ACTUAL, armsInterventionsModule interventions name: thyroid lobectomy, interventions name: image-guided thermal ablation, outcomesModule primaryOutcomes measure: disease progression, primaryOutcomes measure: disease-free survival, secondaryOutcomes measure: complications, secondaryOutcomes measure: procedure time, secondaryOutcomes measure: cost, secondaryOutcomes measure: estimated blood loss, secondaryOutcomes measure: hospitalization, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, hasResults: False
protocolSection identificationModule nctId: NCT06325774, orgStudyIdInfo id: Changhai HHospital, briefTitle: Radical Hypofractionated Radiotherapy for Localized Prostate Cancer, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-04-01, primaryCompletionDateStruct date: 2026-04-01, completionDateStruct date: 2031-04-01, studyFirstPostDateStruct date: 2024-03-22, lastUpdatePostDateStruct date: 2024-03-22, sponsorCollaboratorsModule leadSponsor name: Changhai Hospital, class: OTHER, descriptionModule briefSummary: The aim of this trial is to study the safety outcomes of hypofractionated radiotherapy in treating patients with localized prostate cancer.Hypofractionated radiotherapy delivers higher doses of radiotherapy in a shorter time period, may enabling the killing of more tumor cells with fewer side effects.Accumulating evidence has proven the safety and feasibility of hypofractionated radiotherapy for localized prostate cancer.But for localized prostate cancer,the optimal dose per fraction of hypofractionated radiotherapy is still on its way., conditionsModule conditions: Localized Prostate Cancer, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 20, type: ESTIMATED, armsInterventionsModule interventions name: Hypofractionated radiation therapy, outcomesModule primaryOutcomes measure: Incidence of radiotherapy-related gastrointestinal and urogenital tract adverse events, secondaryOutcomes measure: biochemical progression-free survival (bPFS), secondaryOutcomes measure: local progression-free-survival(LPFS), secondaryOutcomes measure: distant metastasis free survival(DMFS), secondaryOutcomes measure: Overall survival (OS), secondaryOutcomes measure: Quality of life (QoL), eligibilityModule sex: MALE, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Changhai hospital, status: RECRUITING, city: Shanghai, state: Shanghai, zip: 200433, country: China, contacts name: Huojun Zhang, M.D., role: CONTACT, phone: +8613311732399, email: chyyzhj@163.com, contacts name: Huojun Zhang, M.D., role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 31.22222, lon: 121.45806, hasResults: False
protocolSection identificationModule nctId: NCT06325761, orgStudyIdInfo id: SY-5007-I-02, briefTitle: A Study to Evaluate the Food Effects on Pharmacokinetics of SY-5007 Tablets in Healthy Subjects, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04-01, primaryCompletionDateStruct date: 2024-05-01, completionDateStruct date: 2024-05-01, studyFirstPostDateStruct date: 2024-03-22, lastUpdatePostDateStruct date: 2024-03-22, sponsorCollaboratorsModule leadSponsor name: Shouyao Holdings (Beijing) Co. LTD, class: OTHER, descriptionModule briefSummary: This study is a single-center, randomized, open-label, single-dose, two-period, two-treatment crossover trial aimed at evaluating the pharmacokinetic (PK) profiles and safety of SY-5007 tablets administered orally to healthy subjects in both fasting and fed states in China., conditionsModule conditions: Health Subjects, designModule studyType: INTERVENTIONAL, phases: PHASE1, designInfo allocation: RANDOMIZED, interventionModel: CROSSOVER, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 28, type: ESTIMATED, armsInterventionsModule interventions name: SY-5007, interventions name: SY-5007, outcomesModule primaryOutcomes measure: Cmax for SY-5007, primaryOutcomes measure: Tmax for SY-5007, primaryOutcomes measure: AUC0-t for SY-5007, primaryOutcomes measure: AUC0-∞ for SY-5007, primaryOutcomes measure: t½ for SY-5007, primaryOutcomes measure: CL/F for SY-5007, primaryOutcomes measure: Vz/F for SY-5007, secondaryOutcomes measure: Safety of SY-5007, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 55 Years, stdAges: ADULT, contactsLocationsModule locations facility: West China Hospital of Sichuan University, city: Chengdu, state: Sichuan, zip: 610041, country: China, contacts name: Li Zheng, role: CONTACT, phone: 86-28-85423655, email: zhengli@wchscu.cn, geoPoint lat: 30.66667, lon: 104.06667, hasResults: False
protocolSection identificationModule nctId: NCT06325748, orgStudyIdInfo id: SENTI-202-101, briefTitle: SENTI-202: Off-the-shelf Logic Gated CAR NK Cell Therapy in Adults With CD33 and/or FLT3 Blood Cancers Including AML/MDS, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-06, primaryCompletionDateStruct date: 2025-09, completionDateStruct date: 2040-08, studyFirstPostDateStruct date: 2024-03-22, lastUpdatePostDateStruct date: 2024-03-22, sponsorCollaboratorsModule leadSponsor name: Senti Biosciences, class: INDUSTRY, descriptionModule briefSummary: This is an open-label study of the safety, biodynamics, and anti-cancer activity of SENTI-202 (an off-the-shelf logic gated CAR NK cell therapy) in patients with CD33 and/or FLT3 expressing blood cancers, including AML and MDS., conditionsModule conditions: AML/MDS, conditions: CD33 Expressing Hematological Malignancies, conditions: FLT3 Expressing Hematological Malignancies, designModule studyType: INTERVENTIONAL, phases: PHASE1, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 21, type: ESTIMATED, armsInterventionsModule interventions name: SENTI-202, outcomesModule primaryOutcomes measure: Safety and tolerability for dose determination of SENTI-202, secondaryOutcomes measure: Anti-cancer activity of SENTI-202, secondaryOutcomes measure: Pharmacokinetic (PK) and pharmacodynamic (PDn) profile of SENTI-202, secondaryOutcomes measure: Host immune response to SENTI-202, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 74 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06325735, orgStudyIdInfo id: 98, briefTitle: Combined Systemic Inflammatory Indices and Birth Weight, statusModule overallStatus: COMPLETED, startDateStruct date: 2019-12-01, primaryCompletionDateStruct date: 2021-02-01, completionDateStruct date: 2024-04-01, studyFirstPostDateStruct date: 2024-03-22, lastUpdatePostDateStruct date: 2024-04-18, sponsorCollaboratorsModule leadSponsor name: University of Campania "Luigi Vanvitelli", class: OTHER, descriptionModule briefSummary: The study aimed to explore the complex relationship between various systemic inflammatory indices and birth weight, conditionsModule conditions: Systemic Inflammation Markers, conditions: Birth Weight, conditions: Combined Systemic Inflammatory Indices, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 199, type: ACTUAL, armsInterventionsModule interventions name: None intervention, outcomesModule primaryOutcomes measure: Systemic inflammatory indices and birth weight, eligibilityModule sex: FEMALE, minimumAge: 18 Years, maximumAge: 45 Years, stdAges: ADULT, contactsLocationsModule locations facility: Università degli studi della Campania "Luigi Vanvitelli"- OB & Gyn -, city: Napoli, state: Italia, zip: 80138, country: Italy, geoPoint lat: 40.85216, lon: 14.26811, hasResults: False
protocolSection identificationModule nctId: NCT06325683, orgStudyIdInfo id: NCI-2024-01995, secondaryIdInfos id: NCI-2024-01995, type: REGISTRY, domain: CTRP (Clinical Trial Reporting Program), secondaryIdInfos id: A072201, type: OTHER, domain: Alliance for Clinical Trials in Oncology, secondaryIdInfos id: A072201, type: OTHER, domain: CTEP, secondaryIdInfos id: U10CA180821, type: NIH, link: https://reporter.nih.gov/quickSearch/U10CA180821, briefTitle: Anti-Lag-3 (Relatlinib) and Anti-PD-1 Blockade (Nivolumab) Versus Standard of Care (Lomustine) for the Treatment of Patients With Recurrent Glioblastoma, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-06-21, primaryCompletionDateStruct date: 2028-07-15, completionDateStruct date: 2028-07-15, studyFirstPostDateStruct date: 2024-03-22, lastUpdatePostDateStruct date: 2024-03-22, sponsorCollaboratorsModule leadSponsor name: National Cancer Institute (NCI), class: NIH, descriptionModule briefSummary: This phase II trial compares the safety, side effects and effectiveness of anti-lag-3 (relatlinib) and anti-PD-1 blockade (nivolumab) to standard of care lomustine for the treatment of patients with glioblastoma that has come back after a period of improvement (recurrent). Relatlimab and nivolumab are monoclonal antibodies that may interfere with the ability of tumor cells to grow and spread. Lomustine is a chemotherapy drug and in a class of medications called alkylating agents. It damages the cell's deoxyribonucleic acid (DNA) and may kill cancer cells. Relatlinib and nivolumab may be safe, tolerable, and/or effective compared to standard of care lomustine in treating patients with recurrent glioblastoma., conditionsModule conditions: Recurrent Glioblastoma, designModule studyType: INTERVENTIONAL, phases: PHASE2, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 178, type: ESTIMATED, armsInterventionsModule interventions name: Biopsy, interventions name: Biospecimen Collection, interventions name: Lomustine, interventions name: Magnetic Resonance Imaging, interventions name: Nivolumab, interventions name: Relatlimab, interventions name: Surgical Procedure, outcomesModule primaryOutcomes measure: Overall survival (OS), primaryOutcomes measure: OS rate, secondaryOutcomes measure: Progression-free survival (PFS), secondaryOutcomes measure: Radiographic response, secondaryOutcomes measure: Incidence of adverse events (AEs), eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06325670, orgStudyIdInfo id: 23/50374, briefTitle: Type 2 Diabetes and Binge Eating Disorder (BED), statusModule overallStatus: RECRUITING, startDateStruct date: 2024-02-23, primaryCompletionDateStruct date: 2024-12, completionDateStruct date: 2025-06, studyFirstPostDateStruct date: 2024-03-22, lastUpdatePostDateStruct date: 2024-03-22, sponsorCollaboratorsModule leadSponsor name: Odense University Hospital, class: OTHER, collaborators name: Jascha Fonden, collaborators name: Independent Research Fund Denmark, descriptionModule briefSummary: The goal of this research project is to improve the treatment of individuals living with both type 2 diabetes (T2D) and Binge Eating Disorder (BED). The research hypothesizes that BED treatment will not only improve BED symptoms but also improve T2D severity and associated cardiovascular risk factors. The research involves a multidisciplinary team, including experts in endocrinology, psychology, and eating disorders.The main questions it aims to answer are:* Does treatment for Binge Eating Disorder lead to improvements in BED symptoms?* Does treatment for Binge Eating Disorder lead to improvements in T2D severity and associated cardiovascular risk factors?Participants will undergo a comprehensive treatment program targeting both BED and T2D. This program will include psychotherapy sessions focusing on cognitive-behavioral techniques to address binge eating behavior.Researchers will compare participants' outcomes before and after the treatment program to assess changes in BED symptoms, T2D severity, and associated cardiovascular risk factors., conditionsModule conditions: Diabetes Mellitus, Type 2, conditions: Binge-Eating Disorder, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 64, type: ESTIMATED, armsInterventionsModule interventions name: BED treatment, interventions name: Waitlist, outcomesModule primaryOutcomes measure: Number of binge eating episodes, secondaryOutcomes measure: Binge Eating Disorder Questionnaire, secondaryOutcomes measure: Glucose Sensor Data for Blood Glucose Profile, secondaryOutcomes measure: HbA1c, otherOutcomes measure: Eating Disorder Examination Questionnaire (EDE-Q), otherOutcomes measure: Major Depression Inventory (MDI), otherOutcomes measure: Problem Areas In Diabetes (PAID20), otherOutcomes measure: Lipid profile, otherOutcomes measure: Body Mass Index (BMI), otherOutcomes measure: Blood Pressure, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Region Of Southern Denmark Locations, status: RECRUITING, city: Odense, state: Region Of Southern Denmark, zip: 5000, country: Denmark, contacts name: Pernille Fiil Nybo, Cand.psych., role: CONTACT, phone: +45 2042 7108, email: Pernille.Fiil.Nybo@rsyd.dk, contacts name: Jakob Linnet, Dr. med., cand.psych., role: CONTACT, phone: +45 2913 8045, email: jakob.linnet@rsyd.dk, geoPoint lat: 55.39594, lon: 10.38831, hasResults: False
protocolSection identificationModule nctId: NCT06325644, orgStudyIdInfo id: 2023H0258, secondaryIdInfos id: CDMRP-PR212399-G, type: OTHER_GRANT, domain: Departent of Defense, briefTitle: Well-Formulated Ketogenic Diet Polycystic Kidney Disease, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04-01, primaryCompletionDateStruct date: 2026-04-01, completionDateStruct date: 2027-04-01, studyFirstPostDateStruct date: 2024-03-22, lastUpdatePostDateStruct date: 2024-03-22, sponsorCollaboratorsModule leadSponsor name: Ohio State University, class: OTHER, descriptionModule briefSummary: This is a prospective study to determine ketogenic diet effect on htTKV, GFR, microalbuminuria. This is a single-center study of 20 patients with ADPKD and deemed high risk for progression to ESRD. This determined by combination of features of ADPKD and htTKV as assessed by prior computed tomography (CT) or MRI. Patients will be recruited from the Polycystic Kidney Disease (PKD) Clinic at Ohio State University Wexner Medical Center. Enrolled patients will have MRI for htTKV, urinary studies, blood tests at baseline, 6 months, and 52 weeks. Blood for GFR will be assessed three times over the course of the study including baseline, 6 months, and 1 year. Participants will follow ketogenic diet for 52 weeks. Investigatory diet team will manage the ketogenic diet., conditionsModule conditions: Polycystic Kidney Disease, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: BASIC_SCIENCE, maskingInfo masking: NONE, enrollmentInfo count: 20, type: ESTIMATED, armsInterventionsModule interventions name: Ketogenic Diet, interventions name: Ketone/Glucose Monitoring, interventions name: CGM/CKM, interventions name: Blood Draw, interventions name: Body Composition, interventions name: Change in glomerular filtration rate (mg/mmol) via magnetic resonance imaging (MRI) ., outcomesModule primaryOutcomes measure: Finger Stick Beta-Hydroxybutyrate, primaryOutcomes measure: Finger Stick Glucose, secondaryOutcomes measure: Blood Pressure, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 65 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, documentSection largeDocumentModule largeDocs typeAbbrev: Prot, hasProtocol: True, hasSap: False, hasIcf: False, label: Study Protocol, date: 2024-01-07, uploadDate: 2024-03-19T14:40, filename: Prot_000.pdf, size: 409140, largeDocs typeAbbrev: ICF, hasProtocol: False, hasSap: False, hasIcf: True, label: Informed Consent Form, date: 2024-01-07, uploadDate: 2024-03-19T14:40, filename: ICF_001.pdf, size: 428384, hasResults: False